BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

Core Insights - BioCryst Pharmaceuticals has appointed Babar Ghias as the new Chief Financial Officer (CFO) and head of corporate development, bringing extensive experience in deal-making and operational management [1][2] - Ghias has a strong background in the biotech sector, having previously served as CFO at AvenCell Therapeutics and held senior roles at Paragon Biosciences and Marathon Pharmaceuticals, where he raised over $1 billion in capital [3][4][5] - The company aims to leverage Ghias's expertise to accelerate growth and enhance value, particularly through the commercial momentum of its product ORLADEYO and its advancing pipeline [6][8] Company Overview - BioCryst Pharmaceuticals is a global biotechnology company focused on developing therapies for rare diseases, particularly hereditary angioedema [8] - The company has commercialized ORLADEYO (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies [8]